Gaudium IVF and Women Health Limited has submitted to the Exchange, the financial results for the quarter and year ended March 31, 2026.
GAUDIUMIVF · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Gaudium IVF reported strong full-year results for FY26. Consolidated revenue grew 47.5% to ₹10,435.70 Lakhs while standalone revenue increased 21.3% to ₹7,157.85 Lakhs. Profit after tax on consolidated basis rose 27.7% to ₹2,448.85 Lakhs, exceeding the 25% growth threshold. EPS improved from ₹3.12 to ₹3.92. The company successfully completed its IPO in February 2026, raising ₹9,000.08 Lakhs through fresh equity, with most proceeds (₹8,131.20 Lakhs) remaining unutilized as of March 31, 2026. Trade receivables increased significantly to ₹5,337.93 Lakhs (consolidated), indicating potential working capital pressure. Auditors issued an unmodified opinion with no going concern or qualification issues.
The company delivered robust growth exceeding key thresholds on both revenue (47.5%) and PAT (27.7%) basis. The large IPO proceeds sitting unutilized provide significant firepower for expansion. However, the sharp rise in receivables warrants monitoring for cash conversion quality.